Alex Gorsky, J&J CEO (AP Images)
October 4, 2021 07:33 AM EDTUpdated 10:14 AM
Coronavirus

Covid-19 roundup: J&J to ap­ply for boost­er au­tho­riza­tion this week as ad­comms are set; BioN­Tech CEO Ugur Sahin pre­dicts need for new vac­cine for­mu­la­tion

Nicole DeFeudis

Editor

Two weeks af­ter re­leas­ing new da­ta show­ing its Covid-19 boost­er shot bumped pro­tec­tion against mod­er­ate to se­vere dis­ease up to 75% world­wide, J&J is re­port­ed­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times